Micro Medical Solutions, a pioneering medical device company dedicated to improving outcomes for patients with Critical Limb Threatening Ischemia, announced the addition of Vince Burgess and John Dahldorf to its Board of Directors. They join George Quinoy, Chairman and CEO, and Dr. Ron Solar as the company strengthens leadership in preparation for commercial launch of its MicroStent technology.
Health Technology Insights: Revvity Launches Somatic Cancer Standards with MDIC and NIST
George Quinoy, Chairman, President, and CEO, said the company is thrilled to welcome Burgess and Dahldorf. He emphasized that their extensive experience in scaling medical device businesses, guiding public company operations, and executing financial and commercial strategies will be critical as Micro Medical advances through FDA review and prepares for market entry.
Vince Burgess, joining the board in November 2025, served as President, CEO, and Director of Acutus Medical from 2017 to 2022. He previously was a Venture Partner at OrbiMed Advisors and a founding executive at Volcano Corporation, where he led marketing and business development. Burgess also serves on the Board of Directors at Tela Bio and has held positions with Bolt Medical, NeuroPace, Sonendo, Keystone Heart, Vessix Vascular, Cryterion Medical, and CardiAQ. He holds a B.S. in Business Administration from USC and an MBA from UCLA.
Health Technology Insights: City Therapeutics Files CITY-FXI RNAi Trial for Blood Clots
John Dahldorf brings over 25 years of experience leading finance and accounting for public and private healthcare companies. He is currently CFO of Q’Apel Medical and a board member of Hyperfine. Dahldorf previously served as CFO for Volcano Corporation during its acquisition by Royal Philips and has held CFO roles at Digirad, Acutus Medical, SCN Bestco, and Adagio Medical. He holds a B.S. in Finance and an MBA from Western Illinois University.
Dr. Ron Solar, Board Member, said that Burgess and Dahldorf bring proven leadership in innovation, commercialization, and financial strategy that will strengthen MMS’s capacity to execute effectively as the company moves toward FDA approval and market readiness. The MicroStent has received FDA Breakthrough Device Designation and is designed to improve blood flow, support wound healing, and reduce amputations in patients with CLTI. It is currently under Premarket Approval review.
Health Technology Insights: Talkspace Launches Chapters to Support Women’s Mental Health
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
